0001213900-23-064515.txt : 20230808 0001213900-23-064515.hdr.sgml : 20230808 20230808160101 ACCESSION NUMBER: 0001213900-23-064515 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medigus Ltd. CENTRAL INDEX KEY: 0001618500 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37381 FILM NUMBER: 231151042 BUSINESS ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 BUSINESS PHONE: 972722602211 MAIL ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 6-K 1 ea183081-6k_medigus.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023

Commission File Number 001-37381

MEDIGUS LTD.

(Translation of registrant’s name into English)

10 HaNechoshet Street Tel-Aviv, 6971072, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

Medigus Ltd. (the “Company”), hereby announces that the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders scheduled for August 7, 2023 and adjourned to August 8, 2023 (the “Meeting”), as originally proposed and included in the Company’s proxy statement for the Meeting, that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on June 30, 2023.

25,694,490 ordinary shares, representing approximately 9.94% of the Company’s issued and outstanding ordinary shares as of the record date, were present or represented by proxy at the Meeting.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-258624, 333-206803, 333-221019 and 333-229429).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDIGUS LTD.

Date: August 8, 2023	By:	/s/ Tali Dinar
		Tali Dinar
		Chief Financial Officer